Expression of MAGE genes in esophageal squamous-cell carcinoma

Anticancer Research

Volumn 17, Issue 1 A, 1997, Pages 387-391

  Quillien, Veronique ^a,c   Raoul, Jean Luc ^a   Heresbach, Denis ^a   Collet, Brigitte ^a   Toujas, Louis ^a   Brasseur, Francis ^b  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c CENTRE EUGÈNE MARQUIS   (France)

Author keywords

Esophageal squamous cell carcinoma; MAGE 1; MAGE 2; MAGE 3

Indexed keywords

CANCER VACCINE; HLA ANTIGEN CLASS 1; MELANOMA ANTIGEN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ESOPHAGUS CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; INCIDENCE; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; TUMOR CELLS, CULTURED;

EID: 0031043442     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. van der Bruggen P, Traversari C. Chomez P, Lurquin C, De Plaen E and Van den Eynde B: A gene encoding an antigen recoenized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643, 1991.
2. Truvcrsari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P and Van Pel A: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176: 1453, 1992.
3. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora J-P and De Smet C: Structure, chromosomal localization and expression of twelve genes of the MAGE family. Immunogenetics 40: 360, 1994.
4. van der Brusaen P, Szikora JP, Boël P, Wildmann C, Somville M and Sensi M: Autologous cytolytic T lymphocytes recognize a MAGE- 1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur J Immunol 24*2134, 1994.
5. Celis E, Tsai V, Crimi C, De Mars R, Wentworth PA and Chesnut RW: Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 91: 2105, 1994.
6. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ and De Plaen E: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179: 921, 1994.
7. van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boël P and De Smet C: A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24: 3038, 1994.
8. Brasscur F, Rimoldi D, Lienard D, Lethe B, Carrel S and Arienti F: Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 63: 375, 1995.
9. Gutterman JV, Mavligit G, Me Bride C, Frei E, III Freireich EJ and Hersh EM: Active immunotherapy with BCG for recurrent malignant melanoma. Lancet 1: 1208, 1973.
10. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP and Leitman S: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N EngI J Med 316: 889, 1987.
11. Rosenberg SA, Packard BS, Aebersold PM, Solomon D. Topalian SL and Toy ST: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319: 1676, 1988.
12. Brasseur F, Marchand M, Vanwijck R, Herin M, Lethe B and Chomez P: Human gene MAGE- 1, which codes for a tumor rejection antigen, is expressed by some breast tumors. Int J Cancer 52: 839, 1992.
13. Russo V, Traversari C, Verrechia A, Mottolese M, Natali PG, and Bordignon C: Expression of the MAGE gene family in primary and metastatic human breast cancer ; implications for tumor antigenspecific immunotherapy. Int J Cancer 64: 216, 1995.
14. Wevnants P, Lethe B, Brasseur F, Marchand M and Boon T: Expression of MAGE genes by non-small-cell lung carcinomas. Int J Cancer 56: 826, 1994.
15. Shichijo S, Hayashi A, Takamori S, Tsunosue R, Hoshino T and Sakata M: Detection of MAGE-4 protein in lung cancers. Int J Cancer 64: 158, 1995.
16. Patard JJ, Brasseur F, Gil-Diez S, Radvanyi F, Marchand M and François P: Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int J Cancer 64: 60, 1995.
17. Inoue H, Mori M, Honda M, Li J, Shibuta K and Mimori K: The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma. Gastroenterology 109: 1522, 1995.
18. Eura M, Ogi K, Chikamatsu K, Lee KD, Nakano K and Masuyama K: Expression of the MAGE gene family in human head-and-neck squamous-cetl carcinomas. Int J Cancer 64: 304, 1995.
19. Forastiere AA, Orringer MB and Perez-Tamayo C: Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report.J Clin Oncol 11: 1118, 1993.
20. Fuqua SAW, Fitzgerald SD and Me Guire WL: A simple polymerase chain reaction method for detection and cloning of low abondance transcripts. Biotechnique 9: 206, 1990.
21. Hermanek P and Sobin LH, editors: UICC TNM Classification of malignant tumours. 4th ed. 2nd rev. Berlin: Springer-Verlag, 1992.
22. Coulie PG: Antigens recognized on human tumors by cytolytic T lymphocytes: towards vaccination? Stem Cells 13: 393, 1995.
23. Inoue H, Mori M, Li J, Mimori K, Honda M and Nakashima H: Human esophageal carcinomas frequently express the tumorrejection antigens of MAGE genes. Int J Cancer 63: 523, 1995.
24. Rimoldi D, Romero P and Carrel S: The human melanoma antigenencoding gene MAGE-1 is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas. Int J Cancer 54:521, 1993.